Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical
efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus
oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised
adult and pediatric subjects.